The effects of a cyclo-oxygenase II inhibitor on placental artery production of thromboxane and prostacyclin - 28/08/11
, Christine M Kovac, MD a, Byron C Calhoun, MD b, Nathan J Hoeldtke, MD c, Peter G Napolitano, MD a
Reprint requests: Bobby C. Howard, MD, MCHJ-OG, Madigan Army Medical Center, Tacoma, WA 98431.Tacoma, Wash, Rockford, Ill, and Honolulu, Hawaii
Abstract |
Objective |
The study was undertaken to determine the effects of a cyclo-oxygenase II inhibitor on fetoplacental artery production of prostacyclin and thromboxane A2.
Study design |
Eight placentas were obtained from normal parturients at delivery and four chorionic plate arteries were dissected from each placenta. Arteries were incubated in media alone, media plus angiotensin II (1×10−10 mol), media plus rofecoxib (300 ng/mL), or media plus angiotensin II and rofecoxib. Serial samples were assayed for metabolites of thromboxane B2 and prostacyclin by enzyme-linked immunosorbent assay. Results were compared by analysis of variance, and P<.05 was considered significant.
Results |
At 24 hours, 6-keto-prostaglandin F1⍺ levels in the rofecoxib group (1.74±1.39 ng/mg tissue, P<.01) and the rofecoxib plus angiotensin II group (2.15±1.85 ng/mg tissue, P<.01) were significantly lower than levels in the control group (4.25±2.03 ng/mg tissue). Thromboxane B2 levels were lower in the angiotensin II group (0.65±0.33 ng/mg tissue) than the control group (1.22±0.70 ng/mg tissue, P<.05).
Conclusion |
Cyclo-oxygenase II inhibition decreases the production of prostacyclin in fetoplacental arteries and alters the normal ratio of thromboxane A2 to prostacyclin.
Le texte complet de cet article est disponible en PDF.Keywords : Placenta, cyclo-oxygenase II inhibitor, thromboxane, prostacyclin
Plan
 | Supported by the Department of Clinical Investigations at Madigan Army Medical Center. Presented at the Twenty-Third Annual Meeting of the Society for Maternal-Fetal Medicine, San Francisco, Calif, February 3-8, 2003. The opinions and assertions contained herein are the private views of the authors and are not to be construed as official or reflecting the views of the US Army, US Air Force, or Department of Defense. |
Vol 189 - N° 3
P. 835-838 - septembre 2003 Retour au numéro
Article précédent
- Maternal benefit of high-dose intravenous corticosteroid therapy for HELLP syndrome
- James N Martin, Brad D Thigpen, Carl H Rose, Julie Cushman, Amanda Moore, Warren L May
- Fetoplacental vascular tone is modified by magnesium sulfate in the preeclamptic ex vivo human placental cotyledon
- Christine M Kovac, Bobby C Howard, Brian T Pierce, Nathan J Hoeldtke, Byron C Calhoun, Peter G Napolitano
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?